Biophytis (BPTSY) AI Stock Analysis

• Market Cap: $2.46M
• Dividend Yield: N/A
• Average Volume (3M): 52.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: 84.55%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 4,211,828
• 10 Day Avg. Volume: 88
• 30 Day Avg. Volume: 52
• PEG Ratio: 0.02
• Price to Book (P/B): -1.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.79
• Enterprise Value/Market Cap: 3.15
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -34.18
• Enterprise Value/Ebitda: -1.09
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -4.02
• Revenue Forecast (FY): $2.36M

• Rating: 41 Neutral
• Price Target: $0.80 ▲(7.84% Upside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is primarily held down by weak financial performance (no revenue, ongoing cash burn, and negative equity), reinforced by bearish technicals with the stock trading below major moving averages. Valuation is also constrained by negative earnings and no dividend support, with only a minor offset from oversold momentum readings.

Positive Factors

Focused clinical-stage pipeline

Biophytis is a clinical-stage biotech focused on age-related diseases with a clear lead program (Sarconeos/BIO101). A focused R&D portfolio concentrates resources on a single high-value indication, preserving capital and management attention to advance trials and partner/licence outcomes.

Narrowing operating losses

The company materially reduced losses and improved EBIT year-over-year, reflecting durable cost control and tighter spending discipline. Sustained reduction in cash burn lowers near-term financing needs and suggests management can extend runway while advancing clinical programs.

Shareholder approval for strategic actions

Recent shareholder approval of AGM resolutions (noted with a ~31% quorum) provides governance backing to execute financing, licensing or restructuring plans. This structural support improves the company's ability to implement strategic moves to fund and advance development programs.

Negative Factors

No revenue / no commercial product

Biophytis has no product revenues and remains pre-commercial, meaning its long-term viability depends on clinical/regulatory success or partnerships. This structural absence of recurring revenue increases execution risk and prolongs reliance on external funding to sustain operations.

Negative equity and rising debt

Negative equity and an increase in total debt signal balance-sheet fragility and limited solvency cushions. Structurally weak equity positions constrain financing options, can force dilutive capital raises or costly credit, and reduce flexibility to absorb trial setbacks or invest opportunistically.

Persistent cash burn and FCF deficit

Operating and free cash flow remain meaningfully negative despite improvement, indicating core activities consume cash. Ongoing cash burn creates structural dependence on external financings, elevating dilution risk and potentially forcing timing-driven strategic compromises.

Biophytis Business Overview & Revenue Model

Company Description

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

How the Company Makes Money

Biophytis generates revenue through the development and potential commercialization of its drug candidates. The company's revenue model primarily focuses on licensing agreements, partnerships, and collaborations with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Biophytis may receive funding from grants and research collaborations to support its clinical trials and research initiatives. The success of its revenue model is contingent upon the progression and approval of its drug candidates through clinical trials and regulatory processes.

Biophytis Financial Statement Overview

Summary

No revenue and continued losses/cash burn keep fundamentals weak. While 2024 losses and operating cash outflow improved versus 2023, the balance sheet is fragile with negative equity and higher debt, increasing dependence on external financing.

Income Statement

The company has generated no revenue across the provided annual periods, while continuing to post sizable operating losses. Losses have narrowed meaningfully in the most recent year (net loss improved from -$17.0M in 2023 to -$10.4M in 2024, and EBIT improved from -$14.3M to -$8.5M), indicating better cost control, but the business remains structurally unprofitable with no clear top-line traction shown in the statements.

Balance Sheet

Financial leverage and solvency are a key concern: stockholders’ equity is negative in 2024 (-$9.7M) and total assets have fallen sharply (to $6.9M in 2024 from $12.0M in 2023). Total debt increased to $9.8M in 2024 (from $8.3M in 2023), and the negative equity position makes leverage metrics unfavorable and highlights balance-sheet fragility, even though debt is not extremely large in absolute dollars.

Cash Flow

Cash burn remains heavy, with operating cash flow and free cash flow both negative in 2024 (-$8.6M), following -$12.9M operating cash flow in 2023—an improvement, but still meaningfully negative. Free cash flow has tracked close to net loss (both negative), suggesting losses are largely cash-based rather than purely accounting-driven, which increases financing dependence until revenue or materially lower spending is achieved.

Breakdown	Jun 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-803.00K	-484.00K	-311.00K	-280.00K
EBITDA	-8.26M	-13.80M	-22.79M	-26.50M	-13.66M
Net Income	-10.38M	-17.03M	-24.22M	-31.16M	-25.52M
Balance Sheet
Total Assets	6.90M	11.96M	21.99M	36.26M	27.21M
Cash, Cash Equivalents and Short-Term Investments	78.00K	5.93M	11.05M	25.16M	18.77M
Total Debt	9.84M	8.27M	12.13M	16.65M	9.10M
Total Liabilities	16.60M	15.85M	23.90M	30.56M	20.38M
Stockholders Equity	-9.67M	-3.86M	-1.88M	5.83M	2.30M
Cash Flow
Free Cash Flow	-8.64M	-13.09M	-19.13M	-24.14M	-10.08M
Operating Cash Flow	-8.64M	-12.87M	-18.99M	-23.80M	-9.86M
Investing Cash Flow	10.00K	370.00K	-17.00K	12.16M	-12.71M
Financing Cash Flow	3.14M	7.03M	6.13M	29.71M	21.95M

Biophytis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTSY, the sentiment is Negative. The current price of 0.74 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.72, and below the 200-day MA of 1.38, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 38.91 is Neutral, neither overbought nor oversold. The STOCH value of 42.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTSY.

Biophytis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INM	42 Neutral	$2.39M	-0.22	-82.17%	―	-3.27%	51.83%
BPTSY	41 Neutral	$2.46M	-0.07	―	―	―	84.55%
ONCO	33 Underperform	$1.01M	>-0.01	-263.57%	―	-34.58%	96.41%
OGEN	29 Underperform	$3.47M	-0.05	-168.95%	―	―	90.27%

Biophytis Corporate Events

Biophytis Announces Approval of Resolutions at General Meeting

On November 13, 2025, Biophytis announced that all resolutions proposed during their Combined General Meeting were approved, including the financial statements for the fiscal year 2024. This approval, achieved with a shareholder quorum of nearly 31%, reflects strong shareholder support and is pivotal for the company’s strategic initiatives in developing transformative therapies for age-related diseases.

Biophytis Releases Interim Financial Report for H1 2025

On October 31, 2025, Biophytis S.A. released its Interim Financial Report for the first half of fiscal year 2025. This report provides insights into the company’s financial performance, including significant events, research and development activities, and financial position as of June 30, 2025. The report highlights ongoing developments in their drug programs, partnerships, and financing activities, which are crucial for stakeholders to understand the company’s progress and future outlook.